LIXTE Biotechnology Holdings (LIXT) Positions LB-100 as Novel Approach in Cancer Treatment Landscape [Yahoo! Finance]
Favorable Results of Ovarian Cancer Study Presented at Annual Society of Gynecological Care Conference
MissionIRNewsBreaks – LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Files 2025 Form 10-K, Highlights Transformational Year [TheStreet.com]
LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Has the World's Only Clinical-Stage PP2A Inhibitor, Poised to Improve Cancer Treatment Outcomes [TheStreet.com]
LIXTE Biotechnology Files 2025 Annual Report on Form 10K, Provides Operational Highlights of Transformative Year